Abstract Library

#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers

Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Merkel C

Authors: Merkel C, Whicher C, Herrmann K, Jervis N, Ćwikła J,

Keywords: PRRT, peptide receptor radionuclide therapy, radioligand therapy, policy, multidisciplinary care, nuclear medicine, neuroendocrine cancer,

#378 Does TNM Staging Classification Predict Survival in Patients with Small Bowel Neuroendocrine Tumors?

Introduction: Small bowel (SB) NETs are regarded as relatively indolent cancers. ENETS has published TNM staging. This study aims to demonstrate whether the TNM stage predicts survival in this cohort of patients.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Srirajaskanthan R, Ahmed A, Jervis N, O'Sullivan A, Srinivasan P,

Keywords: TNM, survival ,